Maternal Vaccination Shields Newborn Mice From Deadly Superbug

Maternal vaccination could one day shield newborns from one of the deadliest infections on the planet. According to researchers at Washington University School of Medicine in St. Louis, vaccinating pregnant mice protected their newborn pups from lethal bloodstream infections caused by Klebsiella pneumoniae, a drug-resistant superbug that kills thousands of infants in low- and middle-income countries each year and ranks as the leading killer of children worldwide.

The study, published October 14 in the journal Science Advances, reports that more than 80% of pups born to vaccinated mothers survived lethal doses of the bacterium, while none of the pups from unvaccinated mothers survived one strain and fewer than 35% survived the other. There is currently no vaccine against this infection, and the bacterium's growing resistance to antibiotics often leaves doctors without effective treatments.

How the vaccine bridges the newborn immunity gap

Newborns are born with immature immune defenses, leaving a dangerous window of vulnerability in the first weeks of life. The WashU team tested whether a maternal vaccination could close that window. In the study's dosing schedule, female mice were immunized at the time of mating and then once or twice more during pregnancy with a vaccine targeting the K1 and K2 types of K. pneumoniae — two of the most dangerous variants. The vaccine was developed by Omniose, a St. Louis-based startup, and the Rosen lab had previously shown it protects adult mice against liver, respiratory, and bloodstream infections.

Two weeks after birth, the pups were exposed to lethal doses of either the K1 or K2 strain. The protection was striking: while every pup from unvaccinated mothers died after K1 exposure and most died after K2 exposure, more than four in five pups from vaccinated mothers survived either strain. Giving the mothers two doses versus three made no difference to the outcome, suggesting a simpler dosing schedule could suffice.

The researchers also tracked how the protection moved from mother to newborn. Blood drawn weekly from the pups from birth through six weeks of life, plus breast milk collected from nursing mothers, showed high concentrations of vaccine-specific antibodies in both. The first author, staff scientist Paeton Wantuch, explained that pups that received no vaccine themselves were protected by the durable antibodies transferred from their mothers. That transfer — the heart of the maternal vaccination approach — is what makes the strategy so powerful for the earliest weeks of life.

Why it matters — and what comes next

The concept behind the work will feel familiar: maternal vaccination against flu, whooping cough, and respiratory syncytial virus already protects millions of newborns each year. What is new for maternal vaccination here is the target. K. pneumoniae causes severe sepsis in hospitals worldwide, and in lower-income countries it spreads through the environment to children who have no effective medicines left to fight it. A maternal vaccine would sidestep the antibiotic-resistance problem entirely by preventing infection before it starts.

"Klebsiella pneumoniae is a serious threat to newborns who have not yet developed their own immune defenses," said senior author David A. Rosen, an associate professor of pediatrics and of molecular microbiology at WashU Medicine, according to the report on the study. According to Rosen, maternal immunization can bridge that critical window of vulnerability, giving newborns protection right from birth.

The road ahead has clear milestones. The team is now testing updated versions of the vaccine designed to cover more strains of the superbug circulating around the globe. Rosen said the study establishes a practical model that researchers can use to test further therapies and vaccines, bringing maternal vaccination for this superbug closer to human clinical trials with the ultimate goal of improving global health.

A note of caution belongs in the frame: this was a mouse study, and immune responses that look dramatic in rodents do not always translate to humans. The dose count that worked in mice, the timing relative to birth, and the durability of antibodies in human infants all remain open questions that only clinical trials can answer. Still, the size of the effect — from near-certain death to majority survival — is the kind of signal that moves a research program forward.

For a generation that came of age watching vaccines rewritten in real time during the pandemic, the next frontier of maternal vaccination may look less like a shot in your own arm and more like a shot given one generation to protect the next.